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LETTER TO THE EDITOR
CD83 antigen expression and its role in the progression of 
systemic malignancies 
Expressão do antígeno CD83 e o seu papel na progressão de neoplasias sistêmicas
Shailendra KapoorI
Mechanicsville, Virginia, United States
I read with great interest the recent article by Borges et al.1 CD83 may play a major role in 
the progression of systemic tumors other than fibroadenomas. Shorter survival rates are seen 
among patients with gastric carcinomas that demonstrate a lesser number of CD83-positive 
dendritic cells within the tumor.2 In fact, the prognosis and clinical outcome in cases of gastric 
carcinoma is inversely related to the density of CD83-positive dendritic cells.3 Similarly, in cases 
of gallbladder carcinoma, the tumor prognosis is influenced by infiltration of CD83-positive 
dendritic cells. For instance, in a recent study, Furihata et al. determined the CD83 index in gall-
bladder carcinomas by using the formula CD83 (+) DCs/ (CD83 (+) DCs plus CD1a (+) DCs, 
where DC stands for dendritic cell.4 They showed that individuals with a higher CD83 index 
(greater than 0.316) had a better overall prognosis and clinical outcome.
In females with breast carcinomas, an inverse relationship exists between lymph node 
metastasis and CD83-positive dendritic cells. In fact, those who demonstrate higher numbers of 
CD83-positive dendritic cells and also exhibit lymph node metastasis have better survival rates 
than shown by those with smaller numbers of CD83-positive cells.5 Longer “relapse-free sur-
vival” is also seen among individuals with higher CD83 dendritic cell levels. Similarly, in cases 
of cervical carcinoma, higher incidence of CD83 polymorphisms has been noted. Females with 
SNP rs9370729 on CD83 are more likely to develop cervical adenocarcinomas. A similar rela-
tionship is seen between cervical adenocarcinomas and SNP rs75074 on CD83. On the other 
hand, females with the CC genotype of SNP rs750749 on CD83 demonstrate almost half the 
risk of developing cervical malignancies, in contrast with those who exhibit the TT genotype.6 
Higher levels of “soluble CD83” are seen in certain cases of chronic lymphocytic leukemia. 
Disease progression in cases of chronic lymphocytic leukemia may be strongly influenced and 
regulated by “soluble CD83”.7 Recently, CD83 monoclonal antibodies were developed from 9D8 
hybridoma cell lines, and this may prove to be of great benefit in oncology.8 
The above examples clearly illustrate the significance of assessing CD83 status in the above 
tumors and the need for further human studies in this regard. 
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We read the letter to the editor “CD83 antigen expression and its 
role in the progression of systemic malignancies”, that was writ-
ten by Dr. Shailendra Kapoor, with great attention and interest. 
It shows that CD83 antigen expression in dendritic cells should 
represent a clinical marker for progression and prognosis in 
some malignant neoplasms like gastric carcinomas and gallblad-
der carcinomas. The letter also mentions that positive CD83 anti-
gen expression in dendritic cells is inversely related to lymph 
node metastasis in women with breast carcinomas. 
We are grateful to Dr. Kapoor for referring to our article 
in his letter. In fact, this was the first study on this issue in the 
Department of Gynecology, Unifesp, and has led us to great 
interest in CD83 antigen expression and its relationship with 
breast neoplasms.
Currently, new research is underway, with the aim of show-
ing CD83 antigen expression and its significance in cases of 
other breast neoplasms. We consider that positive CD83 antigen 
expression in dendritic cells may be a biological marker relating 
to clinical tumor progression and may also have an important 
role in the immunological response against breast neoplasms.
We totally agree with Dr. Kapoor that this issue deserves 
careful study in order to improve our knowledge and, perhaps, 
open our minds to new thinking in relation to the progression 
and treatment of neoplasms.  
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